Literature DB >> 25417241

Health-care utilization by prognosis profile in a managed care setting: using the Surveillance, Epidemiology and End Results Cancer Survival Calculator SEER*CSC.

Borsika A Rabin1, Jennifer L Ellis2, John F Steiner2, Larissa Nekhlyudov2, Eric J Feuer2, Benjamin F Hankey2, Laurie Cynkin2, Elizabeth Bayliss2.   

Abstract

BACKGROUND: Accurate estimation of the probability of dying of cancer versus other causes is needed to inform goals of care for cancer patients. Further, prognosis may also influence health-care utilization. This paper describes health service utilization patterns of subgroups of prostate cancer and colorectal cancer (CRC) patients with different relative probabilities of dying of their cancer or other conditions.
METHODS: A retrospective cohort of cancer patients from Kaiser Permanente Colorado were divided into three groups using the predicted probabilities of dying of cancer and other causes calculated by the nomograms in the National Cancer Institute Surveillance, Epidemiology and End Results Cancer Survival Calculator. Demographic, disease-related characteristics, and health service utilization patterns were described across subgroups.
RESULTS: The cohort consisted of 2092 patients (1102 prostate cancer and 990 CRC). A new diagnosis of cancer increased utilization of cancer-related services with rates as high as 9.1/1000 person-days for prostate cancer and 36.2/1000 person-days for CRC. Little change was observed in the number of primary and other specialty care visits from prediagnosis to 1 and 2 years postdiagnosis.
CONCLUSIONS: We found that although a new diagnosis of cancer increased utilization of cancer-related services for an extended time period, the timing of cancer diagnosis did not appear to affect other types of utilization. Future research should assess the reason for the lack of impact of cancer and unrelated comorbid conditions on utilization and whether desired outcomes of care were achieved.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2014        PMID: 25417241      PMCID: PMC4841171          DOI: 10.1093/jncimonographs/lgu023

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  21 in total

1.  Trends in follow-up and preventive care for colorectal cancer survivors.

Authors:  Claire F Snyder; Craig C Earle; Robert J Herbert; Bridget A Neville; Amanda L Blackford; Kevin D Frick
Journal:  J Gen Intern Med       Date:  2008-01-16       Impact factor: 5.128

2.  Cancer and comorbidity: redefining chronic diseases.

Authors:  K S Ogle; G M Swanson; N Woods; F Azzouz
Journal:  Cancer       Date:  2000-02-01       Impact factor: 6.860

3.  Patterns of care in early-stage breast cancer survivors in the first year after cessation of active treatment.

Authors:  Jeanne S Mandelblatt; William F Lawrence; Jennifer Cullen; Annette L Stanton; Janice L Krupnick; Lorna Kwan; Patricia A Ganz
Journal:  J Clin Oncol       Date:  2006-01-01       Impact factor: 44.544

4.  The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: validation in a managed care setting.

Authors:  Eric J Feuer; Borsika A Rabin; Zhaohui Zou; Zhuoqiao Wang; Xiaoqin Xiong; Jennifer L Ellis; John F Steiner; Laurie Cynkin; Larissa Nekhlyudov; Elizabeth Bayliss; Benjamin F Hankey
Journal:  J Natl Cancer Inst Monogr       Date:  2014-11

5.  Patterns of comorbidity and the use of health services in the Dutch population.

Authors:  G P Westert; W A Satariano; F G Schellevis; G A van den Bos
Journal:  Eur J Public Health       Date:  2001-12       Impact factor: 3.367

6.  Integrated delivery systems: the cure for fragmentation.

Authors:  Alain C Enthoven
Journal:  Am J Manag Care       Date:  2009-12       Impact factor: 2.229

7.  Under use of necessary care among cancer survivors.

Authors:  Craig C Earle; Bridget A Neville
Journal:  Cancer       Date:  2004-10-15       Impact factor: 6.860

8.  Area-level poverty is associated with greater risk of ambulatory-care-sensitive hospitalizations in older breast cancer survivors.

Authors:  Mario Schootman; Donna B Jeffe; Min Lian; Anjali D Deshpande; William E Gillanders; Rebecca Aft; Walton Sumner
Journal:  J Am Geriatr Soc       Date:  2008-12       Impact factor: 5.562

9.  Surveillance testing among survivors of early-stage breast cancer.

Authors:  Nancy L Keating; Mary Beth Landrum; Edward Guadagnoli; Eric P Winer; John Z Ayanian
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

10.  Health-related quality of life and health care utilisation among older long-term cancer survivors: a population-based study.

Authors:  Floortje Mols; Jan Willem W Coebergh; Lonneke V van de Poll-Franse
Journal:  Eur J Cancer       Date:  2007-08-08       Impact factor: 9.162

View more
  4 in total

1.  Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.

Authors:  Laura L Hester; Steven I Park; William A Wood; Til Stürmer; M Alan Brookhart; Jennifer L Lund
Journal:  Cancer       Date:  2018-12-11       Impact factor: 6.860

2.  Cancer survival: an overview of measures, uses, and interpretation.

Authors:  Angela B Mariotto; Anne-Michelle Noone; Nadia Howlader; Hyunsoon Cho; Gretchen E Keel; Jessica Garshell; Steven Woloshin; Lisa M Schwartz
Journal:  J Natl Cancer Inst Monogr       Date:  2014-11

3.  The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: validation in a managed care setting.

Authors:  Eric J Feuer; Borsika A Rabin; Zhaohui Zou; Zhuoqiao Wang; Xiaoqin Xiong; Jennifer L Ellis; John F Steiner; Laurie Cynkin; Larissa Nekhlyudov; Elizabeth Bayliss; Benjamin F Hankey
Journal:  J Natl Cancer Inst Monogr       Date:  2014-11

4.  Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA.

Authors:  E La Rocca; M Silvestri; G Pruneri; S Di Cosimo; M C De Santis; E Ortolan; M Valenti; S Folli; F G de Braud; G V Bianchi; G P Scaperrotta; G Apolone; M G Daidone; V Cappelletti
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-09       Impact factor: 4.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.